{"id":"W4397009139","doi":"10.1038/s41591-024-02977-w","title":"p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Nerve injury and regeneration","field":"Neuroscience","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"National Institute on Aging; Canadian Institutes of Health Research; Genentech; National Institutes of Health; IXICO; National Institute of General Medical Sciences; H. Lundbeck A/S; Servier; Göteborgs Universitet; Alzheimer's Drug Discovery Foundation; Karolinska Institutet; Vetenskapsrådet; Eisai; Bristol-Myers Squibb; Government of Ontario; Northern California Institute for Research and Education; Pfizer; Biogen; BioClinica; Fondation pour la Recherche sur Alzheimer; Alzheimer's Society; University of Southern California; Hjärnfonden; F. Hoffmann-La Roche; Government of Canada; U.S. Department of Defense; Eli Lilly and Company; Medizinische Universität Graz; Alzheimer's Association; Karl-Franzens-Universität Graz; U.S. Department of Health and Human Services; Foundation for the National Institutes of Health","keywords":"Placebo; Clinical endpoint; Tolerability; Medicine; Randomized controlled trial; Clinical trial; Internal medicine; Oncology; Alzheimer's disease; Pharmacology; Adverse effect; Pathology; Disease","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002372351,0.002062961,0.002618444,0.0004523674,0.0006595913,0.001178191,0.0009102742,0.002677244,0.007310681],"category_scores_gemma":[0.002089063,0.0005218267,0.001868929,0.0004298208,0.001185262,0.001149671,0.0003853189,0.002279723,0.001330703],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007042805,"about_ca_system_score_gemma":0.001350977,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006906837,"about_ca_topic_score_gemma":0.001748026,"domain_scores_codex":[0.9991826,0.0004078153,0.00006096997,0.0001576659,0.00007374412,0.0001170904],"domain_scores_gemma":[0.999154,0.0001952829,0.0002048459,0.00008073703,0.0001054025,0.0002597637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9664225,0.006984009,0.0003463979,0.001179239,0.0009607644,0.00005961819,0.00005453906,0.0001994026,0.00564097,0.000184016,0.001490797,0.01647787],"study_design_scores_gemma":[0.9487406,0.04848849,0.0008713129,0.0000513942,0.0002784937,0.00002575116,0.00001268847,0.0001411298,0.0003138154,0.0001711354,0.0008934284,0.00001175493],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9403995,0.01585844,0.00253354,0.002065308,0.001472565,0.02772936,0.004430286,0.0004029169,0.00510805],"genre_scores_gemma":[0.9434523,0.007280217,0.004936396,0.003258065,0.001219118,0.02913182,0.002374999,0.00005163379,0.008295324],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007310681,"threshold_uncertainty_score":0.02445668,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03304644434149519,"score_gpt":0.3556142142898926,"score_spread":0.3225677699483975,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}